NASDAQ · RGEN
Repligen Corporation
$188.64+$3.95 (+2.14%)
Repligen Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.14% below the high.
Loading market information…
NASDAQ · TKNO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Alpha Teknova, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.66% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Alpha Teknova, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alpha Teknova, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.09+18.18% vs estimate | $9.80M-1.34% vs estimate |
|---|
| Q4 2024 | Mar 4, 2025 | -$0.11+8.33% vs estimate | $9.27M+5.63% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.15-36.36% vs estimate | $9.58M+4.16% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $8.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$188.64+$3.95 (+2.14%)
Repligen Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.14% below the high.
$72.71+$0.02 (+0.03%)
Bio-Techne Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$8.46-$0.04 (-0.47%)
Maravai LifeSciences Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.19% below the high.
$38.61$0.00 (0.0%)
BioLife Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.89% below the high.
$41.27+$0.64 (+1.58%)
Azenta, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.08% below the high.
$133.03+$1.71 (+1.3%)
Mesa Laboratories, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.84% below the high.
$0.62+$0.00 (+0.49%)
Standard BioTools Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.95% below the high.
$8.80+$0.38 (+4.51%)
Harvard Bioscience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.38% below the high.
